Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324054635> ?p ?o ?g. }
- W4324054635 endingPage "637" @default.
- W4324054635 startingPage "637" @default.
- W4324054635 abstract "The early availability of effective vaccines against SARS-CoV-2, the aetiologic cause of COVID-19, has been at the cornerstone of the global recovery from the pandemic. This study aimed to assess the antispike RBD IgG antibody titres and neutralisation potential of COVID-19 convalescent plasma and the sera of Moldovan adults vaccinated with the Sinopharm BBIBP-CorV vaccine. An IgG ELISA with recombinant SARS-CoV-2 spike RBD and two pseudovirus-based neutralisation assays have been developed to evaluate neutralising antibodies against SARS-CoV-2 in biosafety level 2 containment facilities. A significant moderate correlation was observed between IgG titres and the overall neutralising levels for each neutralisation assay (ρ = 0.64, p < 0.001; ρ = 0.52, p < 0.001). A separate analysis of convalescent and vaccinated individuals showed a higher correlation of neutralising and IgG titres in convalescent individuals (ρ = 0.68, p < 0.001, ρ = 0.45, p < 0.001) compared with vaccinated individuals (ρ = 0.58, p < 0.001; ρ = 0.53, p < 0.001). It can be concluded that individuals who recovered from infection developed higher levels of antispike RBD IgG antibodies. In comparison, the Sinopharm-vaccinated individuals produced higher levels of neutralising antibodies than convalescent plasma." @default.
- W4324054635 created "2023-03-14" @default.
- W4324054635 creator A5004706769 @default.
- W4324054635 creator A5010614976 @default.
- W4324054635 creator A5020417989 @default.
- W4324054635 creator A5025985708 @default.
- W4324054635 creator A5034485871 @default.
- W4324054635 creator A5037206592 @default.
- W4324054635 creator A5054085529 @default.
- W4324054635 creator A5056221917 @default.
- W4324054635 creator A5056307602 @default.
- W4324054635 creator A5058895573 @default.
- W4324054635 creator A5067321643 @default.
- W4324054635 creator A5067707207 @default.
- W4324054635 creator A5084976248 @default.
- W4324054635 date "2023-03-13" @default.
- W4324054635 modified "2023-09-30" @default.
- W4324054635 title "Characterisation of the Antibody Response in Sinopharm (BBIBP-CorV) Recipients and COVID-19 Convalescent Sera from the Republic of Moldova" @default.
- W4324054635 cites W2612496103 @default.
- W4324054635 cites W3016269138 @default.
- W4324054635 cites W3017040476 @default.
- W4324054635 cites W3020828664 @default.
- W4324054635 cites W3034202401 @default.
- W4324054635 cites W3036607916 @default.
- W4324054635 cites W3039409489 @default.
- W4324054635 cites W3044702419 @default.
- W4324054635 cites W3048571801 @default.
- W4324054635 cites W3048799641 @default.
- W4324054635 cites W3085504216 @default.
- W4324054635 cites W3087282025 @default.
- W4324054635 cites W3088823112 @default.
- W4324054635 cites W3092403777 @default.
- W4324054635 cites W3092477062 @default.
- W4324054635 cites W3095943393 @default.
- W4324054635 cites W3124827150 @default.
- W4324054635 cites W3131008919 @default.
- W4324054635 cites W3136298903 @default.
- W4324054635 cites W3158999144 @default.
- W4324054635 cites W3160438579 @default.
- W4324054635 cites W3164213165 @default.
- W4324054635 cites W3169964715 @default.
- W4324054635 cites W3178092981 @default.
- W4324054635 cites W3194402687 @default.
- W4324054635 cites W3195498696 @default.
- W4324054635 cites W3195688082 @default.
- W4324054635 cites W3206000828 @default.
- W4324054635 cites W3206892081 @default.
- W4324054635 cites W3207979685 @default.
- W4324054635 cites W3211888797 @default.
- W4324054635 cites W3216089782 @default.
- W4324054635 cites W4200412557 @default.
- W4324054635 cites W4206906054 @default.
- W4324054635 cites W4210545723 @default.
- W4324054635 cites W4213221851 @default.
- W4324054635 cites W4213386340 @default.
- W4324054635 cites W4226035586 @default.
- W4324054635 cites W4229595811 @default.
- W4324054635 cites W4280615675 @default.
- W4324054635 cites W4283445625 @default.
- W4324054635 cites W4292337239 @default.
- W4324054635 cites W4292475725 @default.
- W4324054635 cites W4298147169 @default.
- W4324054635 cites W4307656573 @default.
- W4324054635 cites W4309852665 @default.
- W4324054635 cites W4309890811 @default.
- W4324054635 cites W4311264034 @default.
- W4324054635 doi "https://doi.org/10.3390/vaccines11030637" @default.
- W4324054635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36992221" @default.
- W4324054635 hasPublicationYear "2023" @default.
- W4324054635 type Work @default.
- W4324054635 citedByCount "1" @default.
- W4324054635 countsByYear W43240546352023 @default.
- W4324054635 crossrefType "journal-article" @default.
- W4324054635 hasAuthorship W4324054635A5004706769 @default.
- W4324054635 hasAuthorship W4324054635A5010614976 @default.
- W4324054635 hasAuthorship W4324054635A5020417989 @default.
- W4324054635 hasAuthorship W4324054635A5025985708 @default.
- W4324054635 hasAuthorship W4324054635A5034485871 @default.
- W4324054635 hasAuthorship W4324054635A5037206592 @default.
- W4324054635 hasAuthorship W4324054635A5054085529 @default.
- W4324054635 hasAuthorship W4324054635A5056221917 @default.
- W4324054635 hasAuthorship W4324054635A5056307602 @default.
- W4324054635 hasAuthorship W4324054635A5058895573 @default.
- W4324054635 hasAuthorship W4324054635A5067321643 @default.
- W4324054635 hasAuthorship W4324054635A5067707207 @default.
- W4324054635 hasAuthorship W4324054635A5084976248 @default.
- W4324054635 hasBestOaLocation W43240546351 @default.
- W4324054635 hasConcept C126322002 @default.
- W4324054635 hasConcept C14086860 @default.
- W4324054635 hasConcept C159047783 @default.
- W4324054635 hasConcept C159654299 @default.
- W4324054635 hasConcept C203014093 @default.
- W4324054635 hasConcept C2779134260 @default.
- W4324054635 hasConcept C3007834351 @default.
- W4324054635 hasConcept C3008058167 @default.
- W4324054635 hasConcept C3018027319 @default.
- W4324054635 hasConcept C45189115 @default.
- W4324054635 hasConcept C524204448 @default.